ResMed shares dropped 2.8% in after-market trading despite reporting fiscal fourth-quarter adjusted earnings of $2.95 per share, up 16% year over year and beating the Zacks Consensus Estimate by 1.72%. Full-year adjusted EPS reached $11.17, a 17% increase, while fourth-quarter revenues rose 9% to $1.46 billion, slightly above estimates. For fiscal 2027, the company expects adjusted EPS between $12.00 and $12.25, implying reported growth of about 7% to 10%, with the Zacks Consensus Estimate currently at $12.02 per share. ResMed also projected full-year reported revenues of $5.75 billion to $5.85 billion, below the consensus of $6.03 billion, and noted a roughly $75 million headwind from suspended Astral sales.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
Medpace Holdings IncResMed IncFiscal 2027 revenue guidance below consensus and Astral sales headwind despite EPS beat.
